Confidently advise patients on the treatment of common health conditions
Diabetes mellitus (DM) is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity, or a combination of both factors.
Recently approved drugs for the treatment of diabetes
Sotagliflozin
Despite optimal insulin therapy for patients with type 1 diabetes, adequate glycaemic control may still not be achieved.
Sotagliflozin is a dual inhibitor of SGLT subtypes 1 and 2. It was authorised for use in the EU in 2019 as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes.
How it works
A dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2), sotagliflozin causes:
- Reduced glucose absorption and postprandial glucose (PPG) excursions, and
- Enhanced urinary excretion of glucose through suppressed renal glucose reabsorption
Benefit
Improves glycaemic control with clinical trial evidence showing improvements in HbA1c, weight loss and quality of life with insulin plus sotagliflozin, compared with insulin plus placebo. However, diabetic ketoacidosis has been reported with sotagliflozin, and it should be used with caution in patients at increased risk of diabetic ketoacidosis.
Martindale: The Complete Drug Reference, is available on MedicinesComplete. Search the antidiabetic monographs by their therapeutic use or by drug name for quick access to trusted, evidence-based information. Consult the diabetes mellitus treatment review for global guidance on the diagnosis and management of the disease. Our online clinical content is updated quarterly, ensuring access to the latest medicines information.
Martindale: The Complete Drug Reference provides health professionals with practical, evidence-based, global guidance, allowing the quick comprehension of the characteristics of drugs and their clinical uses. Supporting community pharmacists confidently inform their patients on the safe use of medicines.
